CIK 0000310158 · Large accelerated filer
Merck & Co., Inc.
Sign in to watch- Ticker
- MRK
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NJ
- Entity type
- operating
- EIN
- 221918501
- Phone
- 908-740-4000
- Business address
- 126 EAST LINCOLN AVENUE, P.O. BOX 2000, RAHWAY, NJ, 07065
- Former names
- Merck & Co. Inc., SCHERING PLOUGH CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-14 | Litchfield Caroline EVP & CFO | Sale | −38,291 | $125.50 | $4.8M | 50,908.19 |
| 2024-02-14 | Litchfield Caroline EVP & CFO | Option exercise · Stock Option (Right to Buy) | −38,291 | 0 | ||
| 2024-02-14 | Davis Robert M Chairman, CEO & President | Option exercise | +85,021 | $73.73 | $6.3M | 433,347.76 |
| 2024-02-14 | Davis Robert M Chairman, CEO & President | Sale | −85,021 | $125.40 | $10.7M | 348,326.76 |
| 2024-02-14 | Davis Robert M Chairman, CEO & President | Option exercise · Stock Option (Right to Buy) | −85,021 | 96,760 | ||
| 2024-02-13 | Davis Robert M Chairman, CEO & President | Option exercise | +41,509 | $75.36 | $3.1M | 389,835.76 |
| 2024-02-13 | Davis Robert M Chairman, CEO & President | Option exercise | +108,491 | $73.73 | $8.0M | 498,326.76 |
| 2024-02-13 | Davis Robert M Chairman, CEO & President | Sale | −124,676 | $125.74 | $15.7M | 373,650.76 |
| 2024-02-13 | Davis Robert M Chairman, CEO & President | Sale | −25,324 | $126.37 | $3.2M | 348,326.76 |
| 2024-02-13 | Davis Robert M Chairman, CEO & President | Option exercise · Stock Option (Right to Buy) | −41,509 | 83,020 | ||
| 2024-02-13 | Davis Robert M Chairman, CEO & President | Option exercise · Stock Option (Right to Buy) | −108,491 | 181,781 | ||
| 2024-02-13 | Romanelli Joseph President, Human Health Int?l | Sale | −1,000 | $124.89 | $125K | 19,569.33 |
| 2024-02-09 | Li Dean Y Executive VP & President, MRL | Option exercise | +14,702 | $62.07 | $913K | 60,944.37 |
| 2024-02-09 | Li Dean Y Executive VP & President, MRL | Sale | −14,702 | $125.50 | $1.8M | 46,242.37 |
| 2024-02-09 | Li Dean Y Executive VP & President, MRL | Option exercise · Stock Option (Right to Buy) | −14,702 | 0 | ||
| 2024-02-07 | Williams David Michael EVP,Chief Info&Digital Officer | Sale | −1,451 | $127.57 | $185K | 19,811.67 |
| 2024-02-02 | Oosthuizen Johannes Jacobus President, U.S. Market | Option exercise | +6,773 | $75.36 | $510K | 28,122.35 |
| 2024-02-02 | Oosthuizen Johannes Jacobus President, U.S. Market | Option exercise | +7,045 | $73.73 | $519K | 35,167.35 |
| 2024-02-02 | Oosthuizen Johannes Jacobus President, U.S. Market | Option exercise | +7,119 | $87.10 | $620K | 42,286.35 |
| 2024-02-02 | Oosthuizen Johannes Jacobus President, U.S. Market | Sale | −18,959 | $127.18 | $2.4M | 23,327.35 |
Page 18 of 19 · 376 trades